Raising the Bar for Hemophilia Management
Webcast
1.5 AMA PRA Category 1 Credits™ ...Faculty
OVERVIEW
Raising the Bar for Hemophilia Management is organized by i3 Health.
Dates Available:
September 23, 2025 - September 22, 2026
Statement of Need:
Hemophilia is a rare bleeding disorder caused by a deficiency of coagulation factor VIII (hemophilia A) or coagulation factor IX (hemophilia B), resulting in spontaneous or post-traumatic bleeding episodes that can cause severe complications or even death. The treatment of hemophilia is traditionally based on preventing bleeding through expensive, lifelong infusion therapy with plasma clotting factors, recombinant factors, or monoclonal antibodies (Chernyi et al, 2024). Lack of effective prophylaxis can lead to subsequent disability and irreversible joint damage, known as hemophilic arthropathy. In recent years, the emergence of new therapies, including gene therapy, has revolutionized hemophilia treatment (Gualtierotti et al, 2025). In order to optimize outcomes for their patients, it is crucial for members of the interdisciplinary care team to remain up to date on advances and strategies to balance the benefits of therapy with patients’ quality of life, including improving early detection of hemophilic arthropathy. In this activity, Guy Young, MD (Children’s Hospital Los Angeles and University of Southern California Keck School of Medicine) and Robert F. Sidonio, Jr., MD, MSc (Hemophilia of Georgia Center for Bleeding and Clotting Disorders, Children’s Healthcare of Atlanta), will explore approaches to raising the bar for hemophilia management.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Define appropriate treatment goals and targets for the management of hemophilia A and B
- Evaluate the clinical utility of novel and emerging prophylactic agents for the treatment of individual patients with hemophilia A and B
- Assess methods to improve the early detection of hemophilic arthropathy development and progression
- Apply strategies to enable increased physical activity for patients with hemophilia while minimizing risk of bleeds
ACCREDITATION & CREDITS
Jointly Accredited Provider
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
i3 Health designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 9/22/26. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
A maximum of 1.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 1.5 contact hours of pharmacology credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, for 1.5 ANCC contact hours.
Continuing Pharmacy Education
i3 Health has approved this knowledge-based activity for 1.5 ACPE CE hours. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.
TARGET AUDIENCE
PhysicianNursingPharmacistPhysician AssistantHealthcare ProfessionalsAdvanced Practitioner NursesHematologistNurse PractitionersSPECIALITIES
Haematology
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
Quick Links